Coya Therapeutics Q3 EPS $(0.45) Misses $(0.34) Estimate, Sales $234.134K Beat $85.714K Estimate
Coya Therapeutics Inc COYA
$3.21
▼ -3.60%
($-0.12)
📅 Earnings This Week
Open
$3.24
Prev Close
$3.33
Day Range
$3.15 – $3.48
52W Range
$2.72 – $6.62
Market Cap
$78.11M
Beta
0.75
EPS (TTM)
$-1.07
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2022-12-29 |
| Shares Out. | 23,460,000 |
| Website | coyatherapeutics.com/ ↗ |
| Phone | 18009279800 |
| Employees | 8 |
| Revenue | $243,745 |
| Gross Profit | $243,745 |
| Net Income | -$6.6M |
| Free Cash Flow | -$15.7M |
| Total Assets | $47.3M |
| Total Liabilities | $4.0M |
| Equity | $43.3M |
About Coya Therapeutics Inc
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
Coya Therapeutics Inc is a publicly traded company under the ticker symbol COYA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-11-01)
📰 Latest News for COYA
Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS Meeting
Coya Therapeutics To Highlight ALS Data In Poster Presentation At 2026 Annual NEALS Meeting; Co. Currently Conducts ALSTARS Trial, Phase 2/3, Study To Evaluate COYA 302 For ALS Treatment